Onychomycosis, a fungal infection affecting the nails, impacts 1% to 8% of the general population and 19% to 51.9% of patients undergoing hemodialysis. There is a significant unmet clinical need for advanced onychomycosis therapeutics, as current treatment options, such as oral antifungals and topical agents, often exhibit limited efficacy and prolonged treatment durations. The growing focus on innovative drug delivery systems, targeted therapies, and antifungal agents with improved safety profiles is expected to accelerate the development of onychomycosis drug candidates. According to the onychomycosis pipeline analysis by Expert Market Research, these advancements aim to address the existing gaps in treatment and improve patient outcomes in the coming years.
Major companies involved in the onychomycosis pipeline analysis include Moberg Pharma AB, AmtixBio Co., Ltd., and others.
Leading drugs currently in the pipeline include MOB015B, ATB1651-102, and others.
Due to rising disease prevalence, increased awareness, and advancements in treatment options, the onychomycosis pipeline is poised to grow soon.
The Onychomycosis Pipeline Analysis Report by Expert Market Research gives comprehensive insights into onychomycosis therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for onychomycosis. The onychomycosis report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The onychomycosis pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with onychomycosis treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to onychomycosis.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Onychomycosis is a fungal infection of the nails caused by dermatophytes, yeasts, or non-dermatophyte molds. It occurs due to factors like prolonged exposure to moist environments, trauma to the nails, or underlying conditions such as diabetes. The infection leads to nail discoloration, thickening, and brittleness, significantly affecting patients’ quality of life.
Onychomycosis is typically treated with oral antifungals, such as terbinafine or itraconazole, and topical formulations like ciclopirox or efinaconazole. However, treatment duration is often long, with variable efficacy and potential side effects. Recent advancements focus on targeted therapeutics, improved drug delivery systems, and shorter treatment regimens, aiming to enhance outcomes and address the limitations of existing therapies. Emerging therapies in the pipeline hold promise for better management of the condition. In January 2024, Vanda Pharmaceuticals received approval from the U.S. Food and Drug Administration to initiate clinical trials for VTR-297, a novel topical antifungal candidate for onychomycosis. VTR-297 is a small molecule histone deacetylase inhibitor with antifungal activity, originally derived from Streptomyces hygroscopicus. It targets dermatophytes and fungi, offering a potential new treatment option for nail fungal infections, which have seen limited therapeutic advancements.
Onychomycosis affects 1% to 8% of the global population and 19% to 51.9% of hemodialysis patients. In India, the prevalence ranges from 0.5% to 5%, with dermatophytes causing 90% of cases in the United States and Europe. The rising incidence, especially among diabetic and immunocompromised populations, highlights the urgent need for advanced onychomycosis drug candidates.
This section of the report covers the analysis of onychomycosis drug candidates based on several segmentations, including:
By Phase
The pipeline report covers 50+ drug analyses based on phase:
By Drug Class
The onychomycosis pipeline analysis report covers 50+ drug analyses based on drug classes:
By Route of Administration
The assessment report covers 50+ drug analyses based on the route of administration.
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II and phase IV at 33.33% each, cover a major share of the total onychomycosis clinical trials. demonstrates a strong developmental focus and significant post-marketing evaluations, ensuring long-term safety and effectiveness. Phase I and Phase III each account for 16.67%, indicating early and late-stage innovations. This balanced pipeline can positively impact the onychomycosis market by advancing treatment options and enhancing patient outcomes.
The drug molecule categories covered under the onychomycosis pipeline analysis include small molecules, monoclonal antibodies, peptides, and gene therapies. The onychomycosis report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for onychomycosis. Antifungal-based therapies for onychomycosis are gaining prominence in the drug pipeline to improve treatment outcomes. For instance, Efinaconazole 10% solution , an azole antifungal, is under evaluation for both adult and pediatric patients. Additionally, novel topical formulations and combination regimens are being investigated to enhance nail penetration and minimize systemic exposure.
The EMR report for the onychomycosis pipeline covers the profiles of key companies involved in clinical trials and their drugs under development. It provides a detailed onychomycosis therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is a list of a few players involved in onychomycosis clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for onychomycosis. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of onychomycosis drug candidates.
A Phase 3 multicenter, double-blind study, sponsored by Moberg Pharma AB, aims to evaluate the efficacy and safety of topical MOB015B for treating distal subungual onychomycosis (DSO). With an estimated enrollment of 350 participants, the study involves an 8-week daily treatment followed by a 40-week weekly regimen. MOB-015 delivers concentrated terbinafine topically to the nail and nail bed, optimizing local efficacy while significantly reducing systemic exposure for onychomycosis treatment.
ATB1651, sponsored by AmtixBio Co., Ltd. is in a Phase 2 study that aims to evaluate the safety, tolerability, and pharmacokinetics of ATB1651 in adults with mild to moderate onychomycosis. This randomized, double-blind, placebo-controlled trial will enroll approximately 120 participants. The study is expected to complete primary data collection by June 30, 2025, with overall completion by January 30, 2026. ATB1651 gel enhances antifungal activity by modifying aryl rings, alkyl chains, and methyl groups, disrupting fungal cell membranes and inhibiting growth.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Onychomycosis Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for onychomycosis. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into onychomycosis collaborations, regulatory environments, and potential growth opportunities.
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share